Clinical Trial Update: DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating reducing the dupilumab dose in patients with controlled atopic dermatitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 4 | Status: RECRUITING